截至目前，我们已完成1500多个临床研究，覆盖实体瘤、心血管疾病、呼吸系统等20多个适应症。面对 II、III期这类关键阶段的临床研究，太美智研医药以专业实力担当护航者，为申办者提供强有力支持。 在AI技术的赋能下，更是助力1200多个项目落地互联网患者招募。让 "以患者为中心" 不再是远方，而 是触手可及的服务体验。 而这一切的背后，是我们凝练出的 "6S安全防线"—— 它不只是一套标准，更是我们对每一份研究的专 业"较真"，对每一个生命的科学敬畏。从方案设计到风险管控，从数据监测到结果输出，"安全" 永远 是我们最先划下的底线。 聚焦儿童用药： 9 月 17 日，第七个世界患者安全日如约而至，今年的主题是"安全护理每个新生儿和儿童"。对太美智 研医药而言，这个承载着医疗行业初心的日子，从来不是一句口号——而是我们始终把 "患者放在研究 的中心"，用专业与创新破解临床难题的日常坚守。 从 "患者需求" 出发 让科技成为安全的铠甲 "怎么让治疗更有效？怎么让试验更安全？" 这是我们每次项目启动前，都会反复问自己的问题。 太美智研医药自成立起，"以患者为中心" 就不是挂在墙上的理念，而是贯穿临床研究全流程的行动 ...

Core Viewpoint - Johnson & Johnson aims to establish itself as a leader in the Chinese oncology market, focusing on innovation, collaboration, and patient-centered approaches to enhance its business in the next three years [1] Group 1: Innovation and R&D - Johnson & Johnson is currently the leading company in the blood cancer sector in China and plans to expand its innovation efforts into solid tumors [2] - The company has received approvals for 13 molecules and 26 indications in the oncology field over its 40 years in China, covering key cancers such as prostate cancer and multiple myeloma [2] - Recent breakthroughs in lung cancer treatments include a combination of dual antibodies and small molecule TKI inhibitors, significantly improving objective response rates and overall survival for advanced lung cancer patients [2][3] Group 2: Market Development and Collaboration - Johnson & Johnson's strategy involves deep collaboration with government, hospitals, and industry associations to enhance its market position in solid tumors [4] - The company is conducting real-world studies to gather data on drug efficacy and safety, particularly within the Chinese population, which will inform future R&D [4] - The company is optimizing its distribution channels by focusing on DTP pharmacy networks and training pharmacists to provide comprehensive patient care [4] Group 3: Patient-Centric Approach - Johnson & Johnson emphasizes the importance of making innovations meaningful for patients, ensuring accessibility and affordability of new treatments [7] - The company actively engages with regulatory bodies to expedite drug approval processes and participates in national health insurance negotiations to include its oncology drugs in the national reimbursement list [7] - Initiatives such as the "Tumor Patient Care Specialist" program and customized patient education packages aim to enhance patient experience and support long-term disease management [8]

Financial Data and Key Metrics Changes - Operating revenues surpassed $2,000,000,000 for the first time, reaching $2,020,000,000, which is a 14% increase in constant currency [34][13] - Net profit after tax was $377,200,000, reflecting a 30% increase in constant currency compared to the previous year [34][13] - Gross margin improved to 62.9%, an increase of 1.3% in constant currency [36] Business Line Data and Key Metrics Changes - Hospital business revenue was $1,280,000,000, up 16% in constant currency [34] - Home care business revenue reached $739,900,000, an 11% increase in constant currency [34] Market Data and Key Metrics Changes - The company’s products were used to treat 22 million patients in FY 2025, indicating strong market demand [30] - The manufacturing facility in China became fully operational, contributing to sales [31] Company Strategy and Development Direction - The company focuses on long-term planning, with a perspective extending beyond 15 years, guiding R&D and infrastructure investments [6][8] - Infrastructure investments include the construction of a fifth building at the East Tamaki campus and securing land for a second campus in New Zealand [8][7] - The company aims to double its revenue every five to six years sustainably [60] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of global geopolitics and tariffs but emphasized a long-term strategy to mitigate cost increases through continuous improvements [9][12] - The outlook for FY 2026 anticipates revenue between $2,150,000,000 and $2,250,000,000, with net profit after tax expected to be between $390,000,000 and $440,000,000 [56] Other Important Information - The company is committed to maintaining a prudent balance sheet while investing in R&D and global sales [14] - The board approved a 2% increase in dividends, totaling $0.0425 per share, representing a payout ratio of about 66% [13][14] Q&A Session Summary Question: Why hasn't the company conducted a major investor day like Xero? - The company complies with New Zealand regulations and believes its disclosures are adequate, thus not planning to adopt the Australian remuneration report [66] Question: What are the expectations for FY 2026 underlying profit? - Management referred to the outlook provided earlier, indicating a long-term growth trajectory despite fluctuations during the COVID period [68] Question: How many shareholders voted in favor of the CEO's reelection? - The number of votes will be disclosed at the end of the meeting, but the focus will be on the number of votes rather than individual shareholders [84]

Core Viewpoint - The article highlights the success of Yao Ying Medical, led by Dr. Shi Haoying, emphasizing the importance of high-quality medical services driven by doctors and focused on patient needs [1][6]. Group 1: Medical Core Philosophy - The core of Yao Ying Medical is "doctor-led" care, prioritizing effective and efficient solutions for patients, avoiding unnecessary treatments [3][4]. - The medical team consists of highly qualified professionals, with many having international experience, which enhances the institution's capability to handle complex cases [3][4]. Group 2: Patient-Centric Approach - High-quality medical care is defined as meeting the genuine health needs of patients, focusing on preventive measures and comprehensive health management [4][5]. - The "full-spectrum + specialty" team collaboration model allows for tailored solutions to patient health needs, integrating various medical disciplines [5]. Group 3: International Recognition and Innovation - Yao Ying Medical has gained global recognition, with international patients praising its services and expressing a desire for expansion [6][7]. - The institution actively incorporates cutting-edge medical practices and technologies, such as gene sequencing and AI-assisted health management, to enhance patient care [7]. Group 4: Empowerment of Medical Professionals - The establishment of Yao Ying Medical emphasizes the growth and empowerment of healthcare teams, fostering a collaborative environment focused on patient welfare [9][10]. - The institution attracts top medical talent, creating a culture of continuous improvement and teamwork [9][10]. Group 5: Future Aspirations - Dr. Shi Haoying envisions Yao Ying Medical becoming synonymous with high-quality healthcare in China over the next decade, aiming to reshape the industry with a patient-first philosophy [12].